Skip to content

Hair Changes in Females With Type 2 Diabetes Clinical and Trichoscopic Examination

Evaluation of Hair Changes in Female Patients With Type2 Diabetes Mellitus Versus Non-Diabetic Controls :A Clinical and Dermoscopic Cross-Sectional Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07817277
Acronym
TrichoscopyDM2
Enrollment
130
Registered
2026-09-14
Start date
2026-10-01
Completion date
2027-03-01
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermoscopy, Diabete Mellitus, Female Androgenetic Alopecia

Keywords

Dermoscopy, FPHL, DM2

Brief summary

The aim of this thesis is to investigate the effect of diabetes mellitus on hair by assessing and comparing clinical and dermoscopic hair changes in diabetic patients versus age and sex-matched healthy controls.

Detailed description

The patients will be recruited from the dermatology and endocrinology outpatient clinics of Al-Zahraa University Hospital. Inclusion criteria • Cases: Female patients aged 20-60 years Diagnosed with type 2 diabetes mellitus for at least 1 year HbA1c ≥ 6.5% o Consent to participate * Controls: Age-matched healthy females (no history of diabetes or insulin resistance) Normal fasting blood sugar (\<100 mg/dL) and HbA1c (\<5.7%) No known chronic illness Consent to participate Exclusion Criteria (for both groups) * Current pregnancy or lactation * Thyroid dysfunction * Polycystic ovary syndrome (PCOS) • Anemia (Hb \< 10 g/dL) * History of chemotherapy, radiotherapy, or recent acute illness * Scalp diseases (e.g., tinea capitis, scarring alopecia) * Recent use of drugs known to affect hair growth (e.g., isotretinoin, spironolactone) All patients and control will undergo: 1\. Full history taking 2. Clinical Assessment All participants will undergo generalized dermatological examination including the scalp and body hair. The following aspects will be documented: A. General Scalp Examination • Hair density: visual inspection (reduced, normal) • Scalp condition: erythema, scaling, atrophy, scarring • Presence of inflammation or follicular hyperkeratosis • Hair shaft fragility or breakage • Sebum level: dry, normal, oily B. Hair Loss Type Classification Hair loss will be clinically categorized into one of the following types: 1. Telogen effluvium (TE) Diffuse shedding, positive hair pull test 2. Female pattern hair loss (FPHL) Frontal or vertex thinning with preserved frontal hairline 3. Alopecia areata (AA) Patches of non-scarring alopecia 4. Chronic diffuse hair loss Shedding \>6 months without clear pattern C. Hair Pull Test • Performed by grasping \ 50 hairs from the frontal, parietal, and occipital regions • Considered positive if \>6 hairs are easily extracted • Helps diagnose active shedding, especially in TE 3. Dermoscopic (Trichoscopic) Assessment Dermoscopy will be performed using a handheld dermoscope ( dermasight DS175 -cutechs LLC, Cairo, Egypt ) at 10× magnification, with or without immersion fluid. A. Sites Examined * Frontal scalp (midline, 2 cm behind hairline) * Vertex * Occipital region (serves as internal control) Each site will be examined systematically, and the following features will be documented: B. Dermoscopic Parameters Hair shaft diameter diversity (HSDD) \>20% variation Yellow dots Peripilar signs (brown halos) Short vellus hairs Thin hairs \<30 μm Empty follicular openings Black dots Exclamation mark hairs Broken / dystrophic hairs 4\. Blinding and Reproducibility • Two independent dermatologists will assess dermoscopic images. • In case of disagreement, a third reviewer will be consulted. • Observers will be blinded to diabetic status to minimize bias. 5\. Photographic Documentation • High-resolution digital images of scalp regions 6. Laboratory investigations: The following laboratory serum tests will be done: 1. Complete blood count. 2. serum ferritin. 3. Thyroid stimulating hormone. 4. serum vitamin D3. 5. Erythrocyte sedimentation rate. 6. Glycated hemoglobin.

Interventions

None listed

Sponsors

Al-Azhar University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Cases: * Female patients aged 20-60 years * Diagnosed with type 2 diabetes mellitus for at least 1 year * HbA1c ≥ 6.5% o Consent to participate * Controls: * Age-matched healthy females (no history of diabetes or insulin resistance) * Normal fasting blood sugar (\<100 mg/dL) and HbA1c (\<5.7%) o No known chronic illness * Consent to participate

Exclusion criteria

* Current pregnancy or lactation * Thyroid dysfunction • Polycystic ovary syndrome (PCOS) * Anemia (Hb \< 10 g/dL) * History of chemotherapy, radiotherapy, or recent acute illness * Scalp diseases (e.g., tinea capitis, scarring alopecia) * Recent use of drugs known to affect hair growth (e.g., isotretinoin, spironolactone)

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of Hair Changes in Female Patients with Type 2 Diabetes Mellitus Versus Non-Diabetic Controls: A Clinical and Dermoscopic Cross-Sectional Study1 yearClinical Hair Assessment: 1. Hair loss pattern (diffuse, frontal, vertex, etc.) 2. Duration of hair loss (months/years) 3. Hair pull test results (positive/negative) Dermoscopic (Trichoscopic) Features: 1. Hair shaft diameter variability (%) 2. Presence of yellow dots, white dots, or peripilar signs 3. Follicular density (number/cm²) 4. Miniaturized hair count Metabolic and Laboratory Parameters: 1. BMI (kg/m²) 2. HbA1c (%) 3. Serum Ferritin (ng/mL) 4. Vitamin D3 (ng/mL) 5. TSH (µIU/mL) 6. Hemoglobin (g/dL) 7. ESR (mm/hr) Diabetes-Related Measures: 1. Duration of diabetes (years) 2. Presence of diabetic neuropathy (yes/no) Patient-Reported Outcomes Visual Analog Scale (VAS) for hair loss severity (ludwing scale-sinclair scale) Physician's Global Assessment of hair changes

Countries

Egypt

Contacts

CONTACTHeba khaled younes, resident
drmedhatyoness@gmail.com+201025858377
PRINCIPAL_INVESTIGATORBasma Alsayed risha, lecturer

Al-Azhar University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 15, 2026